ORIGINAL ARTICLESerum HIF-1α and VEGF Levels Pre- and Post-TACE in Patients with Primary Liver Cancer
References (16)
- et al.
Epidemiology and natural history of hepatocellular carcinoma
Best Pract Res Clin Gastroenterol
(2005) - et al.
Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases
Eur J Surg Oncol
(2009) - et al.
PI3K/PTEN signaling I tumorigenesis and angiogenesis
Biochim Biophys Acta
(2008) - et al.
Global cancer statistics, 2002
CA Cancer J Clin
(2005) - et al.
Prognosis of primary liver carcinoma treated with local resection
Chin Med J (Engl)
(2003) - et al.
Angiogenesis in cancer and other diseases
Nature
(2000) - et al.
Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival
World J Gastroenterol
(2005) - et al.
The role of hypoxia-inducible factors in tumorigenesis
Cell Death Differ
(2008)
Cited by (53)
HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization
2023, Digestive and Liver DiseaseEarly assessment of chemotherapeutic response in hepatocellular carcinoma based on serum surface-enhanced Raman spectroscopy
2022, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyCitation Excerpt :Besides, the SERS intensity at 1654 cm−1 of post-therapeutic serum is also larger than that of pre-therapeutic serum in OR group, indicating a raised level of free amino acid (amide I) in serum three days after TACE therapy. The mechanism of TACE therapy is to deliver chemotherapeutic and embolization agents into tumor-feeding artery for selective tumor hypoxia and eventually tumor necrosis [9], further leading to the temporary increment of serum vascular endothelial growth factor (VEGF) [56]. Simultaneously, in hypoxia micro-environment, VEGF can also induce rapid pro-urokinase activation on the surface of endothelial cells, further leading to the extracellular protein hydrolysis and the release of free amino acids in serum [57], which is consistent with the findings in our study.
The therapeutic landscape of hepatocellular carcinoma
2021, MedCitation Excerpt :This dose might depend on different factors, such as the tumor size, the level of hypoxia before the onset of treatment, and other factors.192 During anti-angiogenic treatments and especially after hypoxia-promoting interventions such as transarterial chemoembolization, monitoring hypoxia by quantification of HIF-1α levels in the blood could be helpful to adjust the drug dose.194–196 Anti-VEGF/VEGFR treatments lead to the development of resistance through several mechanisms, such as upregulation of VEGF or other pro-angiogenic factors, which could be targeted in combination therapies with VEGF, including ephrins, placental growth factor, FGFR, p38, and angiopoietin.193,197–200
Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives
2024, United European Gastroenterology JournalThe Role of GNMT and MMP12 Expression in Determining TACE Efficacy: Validation at Transcription and Protein Levels
2024, Journal of Hepatocellular Carcinoma